학술논문
Prospective phenotyping of NGLY1-CDDG, the first congenital disorder of deglycosylation
Document Type
article
Author
Lam, Christina; Ferreira, Carlos; Krasnewich, Donna; Toro, Camilo; Latham, Lea; Zein, Wadih M; Lehky, Tanya; Brewer, Carmen; Baker, Eva H; Thurm, Audrey; Farmer, Cristan A; Rosenzweig, Sergio D; Lyons, Jonathan J; Schreiber, John M; Gropman, Andrea; Lingala, Shilpa; Ghany, Marc G; Solomon, Beth; Macnamara, Ellen; Davids, Mariska; Stratakis, Constantine A; Kimonis, Virginia; Gahl, William A; Wolfe, Lynne
Source
Genetics in Medicine. 19(2)
Subject
Language
Abstract
PurposeThe cytosolic enzyme N-glycanase 1, encoded by NGLY1, catalyzes cleavage of the β-aspartyl glycosylamine bond of N-linked glycoproteins, releasing intact N-glycans from proteins bound for degradation. In this study, we describe the clinical spectrum of NGLY1 deficiency (NGLY1-CDDG).MethodsProspective natural history protocol.ResultsIn 12 individuals ages 2 to 21 years with confirmed, biallelic, pathogenic NGLY1 mutations, we identified previously unreported clinical features, including optic atrophy and retinal pigmentary changes/cone dystrophy, delayed bone age, joint hypermobility, and lower than predicted resting energy expenditure. Novel laboratory findings include low cerebral spinal fluid (CSF) total protein and albumin and unusually high antibody titers toward rubella and/or rubeola following vaccination. We also confirmed and further quantified previously reported findings noting that decreased tear production, transient transaminitis, small feet, a complex hyperkinetic movement disorder, and varying degrees of global developmental delay with relatively preserved socialization are the most consistent features.ConclusionOur prospective phenotyping expands the clinical spectrum of NGLY1-CDDG, offers prognostic information, and provides baseline data for evaluating therapeutic interventions.Genet Med 19 2, 160-168.